Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Apr. 30, 2025 — Semaglutide effectively treats liver disease in two thirds of patients, new research has ... New Human 'Multi-Zonal' Liver Organoids Improve Injury Survival in Rodents Apr. 16 ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

which involved around 800 patients treated with semaglutide or placebo on top of standard care and followed for 72 weeks. MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.